UNSPSC 51292029: Tranylcypromine sulfate

This classification denotes a monoamine oxidase inhibitor with the molecular formula 2C9H11N.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7ZAT6ES870, chemically known as trans,dl-2-phenylcyclopropylamine sulfate but more generally known as tranylcypromine sulfate, which bears US NIH Compound Identifier 26069. European Medicines Agency schedules Tranylcypromine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04930MIG.

UNSPSC 51292029 Tranylcypromine sulfate is a Commodity code that does not align with the recent state and local procurement activity posted under it. The three most recent opportunities—Seminole County's naloxone and drug deactivation systems procurement, Texas HHS's therapeutic pharmacy initiative RFI, and Minnesota's multistate cooperative purchasing agreement for generic pharmaceuticals and OTC products—involve naloxone, broad-based prescription programs, and multi-source generic drugs, none of which match tranylcypromine sulfate, a monoamine oxidase inhibitor antidepressant with a narrow clinical indication. The code shows little relevant recent activity; the tagging appears to be a categorization mismatch rather than evidence of active demand for tranylcypromine sulfate specifically.

The issuing bodies span state health and human services departments (Texas HHS, Minnesota Department of Administration), county health authorities (Seminole County, Florida), and cooperative purchasing alliances serving multiple jurisdictions (MMCAP, which includes Minnesota, Oregon, and other participating states). Geographic activity centers on Texas, Minnesota, and Florida, with secondary participation from states within the MMCAP alliance. Representative solicitations include Seminole County's IFB for 1,900 units of naloxone annually (due July 26, 2023), Texas HHS's RFI on direct-to-manufacturer prescription programs (due April 3, 2026), and MMCAP's RFP for generic pharmaceuticals and OTC products (due March 26, 2026). None of these opportunities directly address tranylcypromine sulfate procurement, and no solicitations tagged to this Commodity code show active demand for the product.